[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Yoo KH, Lee SH, Lee J, Sung KW, Jung HL, Koo HH, Lim DH, Kim JH, Shin HJ: Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy. J Korean Med Sci; 2010 Mar;25(3):458-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy.
  • To determine the impact of treatment protocols on the outcome of central nervous system germ cell tumors (CNS-GCTs), we reviewed the medical records of 53 patients who received front-line chemotherapy from September 1997 to September 2006.
  • Pure germinoma, normal alpha-fetoprotein level and beta-human chorionic gonadotropin level <50 mIU/mL were regarded as low-risk features and the others as high-risk.
  • Our data suggest that risk-adapted intensive chemotherapy may improve the outcome of patients with malignant CNS-GCTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Radiotherapy
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / metabolism. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Risk Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1995 Mar;36(3):459-64; discussion 464-6 [7538635.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • [Cites] J Neurooncol. 1998 May;37(3):229-39 [9524081.001]
  • [Cites] Scand Audiol. 1999;28(3):139-43 [10489862.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):285-91 [16598761.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] Childs Nerv Syst. 2002 Feb;18(1-2):30-7 [11935241.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):369-76 [12872359.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Sep;43 Suppl:i-vii, 1-111 [14705327.001]
  • [Cites] Radiology. 1978 Sep;128(3):745-51 [674649.001]
  • [Cites] Med Pediatr Oncol. 1981;9(4):361-5 [6167845.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):932-40 [2981605.001]
  • [Cites] J Neurooncol. 1985;3(2):147-52 [3897472.001]
  • [Cites] Acta Oncol. 1988;27(1):43-50 [2835067.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):285-90 [3403311.001]
  • [Cites] J Neurosurg. 1989 May;70(5):676-81 [2540291.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Pharmacol Toxicol. 1992 Feb;70(2):143-7 [1508841.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9 [7607968.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):19-23 [8850422.001]
  • (PMID = 20191048.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2826748
  • [Keywords] NOTNLM ; Central Nervous System / Drug Therapy / Neoplasms, Germ Cell and Embryonal / Survival
  •  go-up   go-down


2. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA: Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer; 2000 Feb 1;88(3):637-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with primary central nervous system lymphoma (PCNSL), primitive neuroectodermal tumor (PNET), germ cell tumor, cancer metastasis to the brain, or low or high grade glioma were eligible.
  • Between March 1994 and November 1997, 5 universities treated 221 adult patients with intraarterial chemotherapy with or without osmotic opening of the BBB (2464 procedures).
  • In patients with chemotherapy-sensitive tumors, such as PCNSL, PNET, germ cell tumor, and cancer metastasis to the central nervous system, enhanced delivery results in a high degree of tumor response, with an efficacy profile that is reproducible across multiple centers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Germinoma / drug therapy. Glioblastoma / drug therapy. Glioma / drug therapy. Humans. Injections, Intra-Arterial / adverse effects. Injections, Intra-Arterial / instrumentation. Karnofsky Performance Status. Lymphoma / drug therapy. Magnetic Resonance Imaging. Male. Middle Aged. Neuroectodermal Tumors / drug therapy. Neurologic Examination. Osmosis. Remission Induction. Reproducibility of Results. Safety. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10649259.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 31770; United States / NINDS NIH HHS / NS / R01 NS 33618; United States / NINDS NIH HHS / NS / R01 NS 34608
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


3. Kamoshima Y, Sawamura Y: Update on current standard treatments in central nervous system germ cell tumors. Curr Opin Neurol; 2010 Dec;23(6):571-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on current standard treatments in central nervous system germ cell tumors.
  • PURPOSE OF REVIEW: Various approaches have been used for the management of patients with germ cell tumors (GCTs) in the central nervous system (CNS); however, the optimal treatment of both germinoma and nongerminomatous GCTs remains unknown.
  • This review discusses current management strategies and late effects of therapy for CNS GCTs.
  • RECENT FINDINGS: To reduce the late complications of radiation therapy for patients with germinoma, many investigators have introduced dose reduction of radiation therapy in association with platinum-based chemotherapy.
  • In addition, the radiation field has been restricted to the whole ventricular area for localized germinoma.
  • This type of combination therapy has shown promising results and preserves cognitive function and quality of life.
  • SUMMARY: The 10-year survival rate of CNS germinoma is approximately 90%.
  • Most patients with CNS GCTs are children and young adults.
  • Therefore, with the improving life prognosis of young patients, secondary neoplasms, secondary cerebral vasculopathy, neurocognitive deficits, and many other adverse effects induced by the initial treatments are problems to be solved in the next decade.
  • [MeSH-major] Antineoplastic Protocols / standards. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Humans. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885323.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F: Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother; 2004 Feb;38(2):242-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report a case of acute central nervous system (CNS) toxicity with multiple hemorrhages restricted to the corpus callosum associated with combination therapy of cisplatin, ifosfamide, and etoposide.
  • An objective causality assessment revealed that an adverse drug reaction was probable.
  • DISCUSSION: Neurotoxicity has been associated with the administration of various antineoplastic agents.
  • In particular, cisplatin and ifosfamide can cause both acute and delayed CNS toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Intracranial Hemorrhages / chemically induced. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Corpus Callosum / radionuclide imaging. Etoposide / administration & dosage. Germinoma / drug therapy. Humans. Ifosfamide / administration & dosage. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14742759.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 29
  •  go-up   go-down


5. Silvani A, Eoli M, Salmaggi A, Lamperti E, Fariselli L, Milanesi I, Broggi G, Solero CL, Giombini S, Boiardi A: Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study. J Neurooncol; 2005 Feb;71(3):271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study.
  • For the solitary germinoma the target volume was the gross tumour volume.
  • In the five multifocal germinoma patients the whole ventricle volume was irradiated.
  • For the single disseminated germinoma patient we treated the whole central nervous system.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Germinoma / drug therapy. Germinoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Chemotherapy, Adjuvant / methods. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Female. Giant Cell Tumors / drug therapy. Giant Cell Tumors / therapy. Humans. Male. Middle Aged. Pineal Gland / pathology. Radiation Dosage. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Jan;88(1):66-72 [9420074.001]
  • [Cites] Funct Neurol. 1987 Apr-Jun;2(2):189-94 [3666548.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1020-2 [12066901.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):358-63 [10449559.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):857-65 [11821471.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):222-7 [9293454.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):262-6 [9254091.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):245-53 [10930010.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):400-5 [1999710.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):783-8 [10098433.001]
  • [Cites] No Shinkei Geka. 2002 Sep;30(9):935-42 [12233091.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):505-10 [9112445.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):940-4 [8039122.001]
  • [Cites] Radiology. 2001 Feb;218(2):452-6 [11161161.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):511-5 [9112446.001]
  • [Cites] Singapore Med J. 2002 Apr;43(4):182-8 [12188062.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):915-23 [9276355.001]
  • [Cites] Acta Neurochir (Wien). 1991;109(1-2):78-83 [2068974.001]
  • [Cites] Gan No Rinsho. 1986 Sep;32(11):1387-93 [2430119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):511-8 [12738328.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] J Neurosurg. 1989 May;70(5):707-13 [2709111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):429-33 [2394620.001]
  • [Cites] Curr Treat Options Neurol. 2002 Mar;4(2):139-145 [11827646.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):984-9 [7947108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • (PMID = 15735916.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL: Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol. J Clin Oncol; 2004 Mar 1;22(5):846-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / pathology. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Cohort Studies. Confidence Intervals. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Female. Germinoma. Humans. Infusions, Intravenous. International Cooperation. Male. Middle Aged. Probability. Prognosis. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14990640.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement